急性白血病多药耐药研究进展  

Advances in Research of Multidrug resistance in Acute Leukemia

作　　者：吴遐[1] 王俊和[1] 

机构地区：[1]安徽省蚌埠医学院第二附属医院血液科,233040

出　　处：《中华全科医学》2010年第11期1440-1441,1456,共3页Chinese Journal of General Practice

摘　　要：肿瘤细胞对多种化疗药物产生交叉耐药性称为多药耐药(multidrug resistance,MDR),它是造成急性白血病治疗效果不良甚至化疗失败的重要原因。近20多年大量研究发现多药耐药的发生除了经典的MDR1还存在多种机制、多个环节,它们可以是独立存在,也可两种或多种因素联合作用引起多药耐药。因此,对MDR机制研究成为急性白血病治疗上亟待解决的问题,它可以帮助制定有效的治疗方案,从而改善白血病患者的治疗效果。Multidrug resistance（MDR）,which is defined as cross resistance of tumor cells to many chemotherapy drugs,is a primary obstacle to the successful treatment of acute leukemia.Many studies have revealed numbers of mechanisms besides MDR1 involved in multidrug resistance in the past 20 years.Some are independent,some are joint action.Therefore,lessons learned from investigation of cellular defense strategies hold promise for a renaissance in the establishment of therapeutic regimen and development in treatment of acute leukemia.

关 键 词：多药耐药 化疗 急性白血病 

分 类 号：R733.71[医药卫生—肿瘤] R730.53[医药卫生—临床医学]